Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Castle Biosciences ( (CSTL) ) has issued an announcement.
On Jan. 11, 2026, Castle Biosciences reported preliminary, unaudited results for the fourth quarter and full year ended Dec. 31, 2025, indicating 2025 total revenue is expected to exceed $340 million, above its prior guidance of $327–335 million, driven by strong growth in its core tests DecisionDx-Melanoma and TissueCypher, whose combined test volumes rose 37% year over year. The company also highlighted a 42% year-over-year increase in fourth-quarter core test reports, robust adoption of its November 2025 limited-access launch of AdvanceAD-Tx for atopic dermatitis, and an expected year-end 2025 liquidity position of roughly $300 million in cash, cash equivalents and marketable securities, while noting headwinds from Medicare coverage changes for DecisionDx-SCC and the discontinuation of its IDgenetix test in May 2025 as it refocuses its portfolio and reinforces its balance sheet ahead of planned growth in 2026.
The most recent analyst rating on (CSTL) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Castle Biosciences stock, see the CSTL Stock Forecast page.
Spark’s Take on CSTL Stock
According to Spark, TipRanks’ AI Analyst, CSTL is a Neutral.
Castle Biosciences’ overall score is driven by strong technical momentum and positive earnings call highlights, including increased revenue guidance and successful product launches. However, financial performance and valuation concerns, such as negative profitability and a high P/E ratio, weigh on the score.
To see Spark’s full report on CSTL stock, click here.
More about Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a diagnostics company focused on dermatologic and gastroenterological diseases, developing advanced molecular tests such as DecisionDx-Melanoma, TissueCypher Barrett’s Esophagus, DecisionDx-SCC, MyPath Melanoma, DecisionDx-UM and the recently launched AdvanceAD-Tx to guide personalized treatment decisions and improve patient outcomes.
Average Trading Volume: 412,882
Technical Sentiment Signal: Buy
Current Market Cap: $1.15B
See more data about CSTL stock on TipRanks’ Stock Analysis page.